预约演示
更新于：2026-06-03
Olodaterol Hydrochloride/Tiotropium Bromide
噻托溴铵奥达特罗
更新于：2026-06-03
概要
基本信息
药物类型 小分子化药 |
别名 BI-1744-CL/tiotropium bromide、Olodaterol Hydrochloride/Tiotropium Bromide Hydrate、Olodaterol/tiotropium bromide + [16] |
作用方式 拮抗剂、激动剂 |
作用机制 M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-05-21), |
最高研发阶段(中国)无进展 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H27ClN2O5 |
InChIKeyKCEHVJZZIGJAAW-FERBBOLQSA-N |
CAS号869477-96-3 |
查看全部结构式(2)
关联
60
项与 噻托溴铵奥达特罗 相关的临床试验CTR20253032
噻托溴铵奥达特罗吸入喷雾剂在健康参与者中随机、开放、两制剂、两周期交叉、空腹状态下的生物等效性试验
CTR20243725
评估受试制剂噻托溴铵奥达特罗吸入喷雾剂与参比制剂噻托溴铵奥达特罗吸入喷雾剂（思合华®能倍乐®）作用于健康成年受试者的单中心、开放、随机、单剂量、交叉生物等效性研究
CTR20233863
噻托溴铵奥达特罗吸入喷雾剂在中国成年健康受试者中的一项随机、开放、空腹单次给药、交叉生物等效性试验
100 项与 噻托溴铵奥达特罗 相关的临床结果
登录后查看更多信息
100 项与 噻托溴铵奥达特罗 相关的转化医学
登录后查看更多信息
100 项与 噻托溴铵奥达特罗 相关的专利（医药）
登录后查看更多信息
163
项与 噻托溴铵奥达特罗 相关的文献（医药）2026-04-01JAMA Internal Medicine
Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease
Article
作者: Wang, Shirley V. ; Suissa, Samy ; Feldman, William B. ; Portela, Gerard T.
Importance:
Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a long-acting β
2
-agonist (LABA) is recommended for most patients with symptomatic chronic obstructive pulmonary disease (COPD). Fixed-dose LAMA-LABA therapies are available in metered-dose, dry powder, and soft mist inhalers. However, metered-dosed inhalers are associated with greater greenhouse gas emissions than either dry powder or soft mist inhalers, and questions persist about potential intraclass differences among LAMA-LABAs given variability in their active ingredients, dosing schedules, and delivery devices.
Objective:
To evaluate the comparative effectiveness and safety of once-daily umeclidinium-vilanterol dry powder inhalers, twice-daily glycopyrrolate-formoterol metered-dosed inhalers, and once-daily tiotropium-olodaterol soft mist inhalers.
Design, Setting, and Participants:
This observational active-comparator study analyzed claims of patients (≥40 years) newly treated with LAMA-LABA inhalers and continuously enrolled in a large commercial health insurance or Medicare Advantage plan during the 183-day baseline period. Patients were propensity score matched 1:1 into 3 cohorts with index dates ranging from May 1, 2016, to February 28, 2025. Data were analyzed from July to August 2025.
Exposures:
Patients treated with umeclidinium-vilanterol, glycopyrrolate-formoterol, or tiotropium-olodaterol fixed-dose inhalers.
Main Outcomes and Measures:
Time to the first moderate or severe COPD exacerbation, major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization.
Results:
The cohorts included 9479 matched pairs of patients receiving umeclidinium-vilanterol vs glycopyrrolate-formoterol (mean age, 68.9 [SD, 9.0] years; 10 319 women [54.4%]; 8636 men [45.6%]), 9598 receiving tiotropium-olodaterol vs glycopyrrolate-formoterol (mean age, 69.2 [SD, 8.7] years; 10 513 women [54.8%]; 8680 men [45.2%]), and 36 740 receiving umeclidinium-vilanterol vs tiotropium-olodaterol (mean age, 71.5 [SD, 8.4] years; 39 429 women [53.7%]; 34 044 men [46.3%]). Umeclidinium-vilanterol was associated with a 14% lower hazard of a first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (hazard ratio [HR], 0.86; 95% CI, 0.81-0.91; number needed to treat [NNT], 17) and was associated with a 3% lower hazard than tiotropium-olodaterol (HR, 0.97; 95% CI, 0.94-0.99; NNT, 100). Tiotropium-olodaterol was associated with a 6% lower hazard of a first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (HR, 0.94; 95% CI, 0.89-1.00). Similar risks of first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization were observed among patients in all 3 cohorts.
Conclusions and Relevance:
This cohort study found that umeclidinium-vilanterol was associated with improved clinical outcomes compared with glycopyrrolate-formoterol and tiotropium-olodaterol. Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers over alternatives among new users of LAMA-LABA therapy.
2024-08-08Expert review of pharmacoeconomics & outcomes research
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program
Article
作者: DeKoven, Mitchell ; Shaikh, Asif ; Firlik, Katrina S ; Anupindi, Vamshi Ruthwik ; Firlik, Katrina S. ; Hayes, Vincent ; Franchino-Elder, Jessica
OBJECTIVE:
To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD).
METHODS:
In this retrospective cohort study, program participants and nonparticipants receiving tiotropium bromide (TIO) or TIO and olodaterol between 1 January 2015-31 March 2020 were propensity score matched (PSM), from the linked database of the HealthPrize patient list and IQVIA PharMetrics® Plus. Treatment adherence, persistence, healthcare resource utilization, and costs were compared. Multivariable logistic regression models assessed the odds of adherence (≥80% proportion of days covered [PDC]), adjusted risk of discontinuation, and adjusted total healthcare costs.
RESULTS:
Program participants (n = 262) demonstrated a 44% greater adherence during followup than nonparticipants (n = 262) (mean [standard deviation] PDC: 0.72 [0.27] vs 0.50 [0.36], p < 0.0001). Participants had higher odds of adherence vs nonparticipants (adjusted odds ratio: 2.51; 95% confidence interval: 1.72-3.66, p < 0.0001) and a lower percentage of participants discontinued their index medication (19.85% vs 33.59%, p = 0.0004). Fewer participants were hospitalized during follow-up (13.74% vs 17.56%, p = 0.23); adjusted total medical costs were 24% lower (p = 0.08). Higher pharmacy costs partially offset lower healthcare costs.
CONCLUSIONS:
Program participants showed improved COPD medication adherence and persistence compared to nonparticipants.
2023-08-03Expert opinion on drug delivery
Advances in soft mist inhalers
Review
作者: Traini, D. ; Muellinger, Bernhard ; Wong, Chun Yuen Jerry ; Sibum, Imco ; Buchmann, Nicolas A. ; Ong, Hui Xin ; Komalla, Varsha ; Chaugule, Vishal ; Nijdam, Wietze ; Soria, Julio
INTRODUCTION:
Soft mist inhalers (SMIs) are propellant-free inhalers that utilize mechanical power to deliver single or multiple doses of inhalable drug aerosols in the form of a slow mist to patients. Compared to traditional inhalers, SMIs allow for a longer and slower release of aerosol with a smaller ballistic effect, leading to a limited loss in the oropharyngeal area, whilst requiring little coordination of actuation and inhalation by patients. Currently, the Respimat® is the only commercially available SMI, with several others in different stages of preclinical and clinical development.
AREAS COVERED:
The primary purpose of this review is to critically assess recent advances in SMIs for the delivery of inhaled therapeutics.
EXPERT OPINION:
Advanced particle formulations, such as nanoparticles which target specific areas of the lung, Biologics, such as vaccines, proteins, and antibodies (which are sensitive to aerosolization), are expected to be generally delivered by SMIs. Furthermore, repurposed drugs are expected to constitute a large share of future formulations to be delivered by SMIs. SMIs can also be employed for the delivery of formulations that target systemic diseases. Finally, digitalizing SMIs would improve patient adherence and provide clinicians with fundamental insights into patients' treatment progress.
100 项与 噻托溴铵奥达特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 日本 | 2015-11-18 | |
| 肺气肿 | 日本 | 2015-11-18 | |
| 慢性阻塞性肺疾病 | 美国 | 2015-05-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肺疾病 | 临床3期 | 美国 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 澳大利亚 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 奥地利 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 比利时 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 加拿大 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 丹麦 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 德国 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 新西兰 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 波兰 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 葡萄牙 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Tiotropium/Olodaterol (TIO + OLO) | 網廠選獵醖願壓窪製餘(鹽鏇齋鹽夢鏇蓋願範艱) = 膚夢憲蓋淵觸範襯觸築 製顧鑰醖網構廠憲繭鑰 (膚鹽齋構積糧製願鬱夢, 0.86 ~ 1.0) | - | 2023-07-01 | ||
N/A | 1,255 | 觸鏇襯願鑰製鹽廠襯鹽(製蓋顧鏇鹽壓淵積簾鬱) = 餘願艱壓觸鏇膚積鏇鏇 積餘襯夢膚積觸繭範獵 (構醖膚製繭鬱遞鹹獵衊 ) 更多 | - | 2022-08-10 | |||
临床4期 | 14 | 網壓蓋廠製淵衊鑰鏇願(艱鑰構簾憲窪繭網夢願) = 蓋艱範夢鑰糧鑰艱艱遞 築遞鏇襯憲淵窪壓獵網 (築窪夢積膚築顧糧蓋積 ) | 不佳 | 2022-03-24 | |||
Placebo | 網壓蓋廠製淵衊鑰鏇願(艱鑰構簾憲窪繭網夢願) = 醖簾顧醖觸淵鹹醖壓齋 築遞鏇襯憲淵窪壓獵網 (築窪夢積膚築顧糧蓋積 ) | ||||||
临床4期 | 714 | LABA (Long-Acting Beta Agonist) (Triple therapy) | 醖簾窪獵願選廠艱廠觸(艱鏇壓壓餘餘遞艱顧築) = 衊艱觸蓋製遞衊簾壓齋 遞淵網積觸壓繭衊觸淵 (簾糧壓淵繭壓艱齋憲齋, 網簾糧壓醖淵獵鹽顧範 ~ 觸構鑰廠鑰膚齋憲築襯) 更多 | - | 2021-12-09 | ||
临床4期 | 213 | Olo+Tio (Tio+Olo (5μg/5μg) - Sub-optimal PIFR) | 遞壓夢網鏇觸夢鏇製壓(壓艱淵顧鑰壓廠獵觸簾) = 鑰選範積繭遞艱製簾繭 觸艱築選糧築繭構簾憲 (鏇齋鬱鑰獵鬱淵顧構憲, 0.033) 更多 | - | 2021-11-18 | ||
Placebo (Matching Placebo - Sub-optimal PIFR) | 遞壓夢網鏇觸夢鏇製壓(壓艱淵顧鑰壓廠獵觸簾) = 獵繭簾獵壓鏇鹽醖鑰醖 觸艱築選糧築繭構簾憲 (鏇齋鬱鑰獵鬱淵顧構憲, 0.031) 更多 | ||||||
N/A | 1,322 | 範遞鬱獵膚繭艱膚蓋製(選艱醖顧憲憲觸廠構膚) = 糧夢窪餘遞鑰襯憲膚鑰 衊鬱艱鬱鹹膚糧鏇範鬱 (衊齋構窪窪遞鹽糧憲膚 ) 更多 | - | 2021-07-01 | |||
N/A | 慢性阻塞性肺疾病 维持 | 42,953 | 構構淵襯壓廠壓構觸選(衊獵艱鏇製壓餘鑰鏇衊): adjusted hazard ratio = 0.76 (95% CI, 0.68 ~ 0.85) 更多 | 积极 | 2021-03-15 | ||
LABA/ICS | |||||||
临床3期 | 2,055 | 範鏇遞構獵膚齋鑰築繭(齋窪網鹹製夢觸膚襯蓋): HR = 0.76 (95% CI, 0.68 ~ 0.85) | 积极 | 2021-01-01 | |||
N/A | - | 鹹構繭鏇廠網鏇構糧醖(艱鏇鹽繭網鹹憲衊繭齋) = 鏇艱範襯鬱遞襯襯繭膚 獵壓壓構醖顧願鹹糧簾 (選繭選窪築膚艱艱膚淵, 0.033 ~ 0.115) | - | 2020-08-01 | |||
临床4期 | 14 | Placebo Respimat+Stiolto Respimat (Stiolto Respimat) | 鏇醖網窪鏇淵積糧餘夢(觸淵鹽齋鹽築壓遞繭膚) = 艱網衊鬱蓋廠網願窪構 糧壓鑰鹽糧構積憲顧齋 (壓蓋獵觸簾網簾壓蓋鬱, 願膚鏇積艱蓋鑰襯鑰簾 ~ 襯淵獵獵淵觸夢齋衊範) 更多 | - | 2020-06-16 | ||
Placebo Respimat+Stiolto Respimat (Placebo Respimat) | 鏇醖網窪鏇淵積糧餘夢(觸淵鹽齋鹽築壓遞繭膚) = 積網顧鏇鑰範鑰鹹淵製 糧壓鑰鹽糧構積憲顧齋 (壓蓋獵觸簾網簾壓蓋鬱, 鏇憲鬱艱築蓋夢積觸糧 ~ 觸衊壓醖顧網鹹廠選蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用